2014 presenters/Sponsored meetings


December 10, 2014 - ATOSSA Genetics, Inc.
Atossa Genetics, Inc. (NASDAQ: ATOS) offered an informative and impressive presentation at The Stock & Bond Club. Here is some information on the company: Atossa Genetics is passionate about improving breast health and the overall well-being and health of women with whom we are associated with globally. Our focus has been and will continue to be on maintaining our position through the development of a suite of medical devices, therapeutics and laboratory developed procedures (LDPs) in those areas where we can make a difference in health, education and our community with respect to breast health. Visit www.atossagenetics.com

Pluristem Therapeutics - (NASDAQ: PSTI) Presented before The Stock & Bond Club. COMPANY OVERVIEW: Pluristem Therapeutics Inc. is a clinical-stage biotechnology company using placental cells and a unique, proprietary, three-dimensional (3D) technology platform to develop cell therapies for a broad spectrum of diseases. Pluristem derives its cell products from human placental cells. These cells are converted into PLacental eXpanded (PLX) cells, which secrete therapeutic proteins in response to signals produced by damaged tissues. Pluristem’s pipeline targets multiple indications involving inflammation and ischemia, including peripheral artery disease, muscle injury, preeclampsia, and graft versus host disease. PLX cells require no tissue matching prior to administration, making them an “off-the-shelf” product. The company’s GMP-certified in-house manufacturing facilities allow it to efficiently produce commercial quantities of homogeneous, clinical-grade PLX cells. Pluristem is currently the only company manufacturing large quantities of placenta-based cell products using a 3D bioreactor. Driving these development efforts is a management team dedicated to shaping the future of the company and of placenta-based cell therapies. The Pluristem team has many decades of industry and research experience and draws on this as it continues to progress towards company goals. http://www.pluristem.com

November 13, 2014 - IMMUNE Pharmaceuticals
IMMUNE Pharmaceuticals, (NASDQ: IMNP), presented before Stock & Bond Club. Shown receiving lifetime membership award: Dr. Daniel Teper, founder and CEO of IMMUNE Pharmaceuticals & Carlo Corzine, President of The Stock & Bond Club. www.immunepharmaceuticals.com 

October 28, 2014 - iWallet
iWallet presented before Stock & Bond Club 28 October ’14. iWallet (IWAL, $0.60) presented before the Stock & Bond Club of South Florida. CEO Jack B. Chadsey outlined the companies growth and branding strategies. iWallet Corporation designs and develops security products to protect against identity, personal, and financial information theft in the United States. The company offers biometric locking wallet that protects cash, credit cards, and personal information with a proprietary fingerprint security system. The company was founded in 2009 and is headquartered in San Diego, California. www.iwalletusa.com

April 2, 2014 - Juhl Energy
Juhl Energy presented at The Stock & Bond Club on Wednesday, April 2, 2014. The Stock and Bond Club of South Florida (“SBCSF”) was pleased to host JUHL ENERGY (OTCQB:JUHL), at the Boca Raton Country Club. JUHL is a renewable energy company, specializing in Wind Power, with related interest in and offshoots into Solar and Co-Generation projects. Together with its parent, the Company has developed and operates a fleet of more than 24 wind farms and has produced predictable cash flows for 9 consecutive quarters with strong revenue diversification. In several cases, the Company had worked with Marquis-name companies and partners. JUHL is currently raising an additional $3 million of Capital at this time and it is offering a 9% yield on a New Class of Preferred stock. The SBCSF compliments JUHL’s President, John Mitola, for his excellent and informative presentation, and it appreciates JUHL subsidizing our Members’ dinner cost. We are pleased to confirm Mr. Mitola and JUHL Energy as Lifetime Members. www.juhlenergy.com

March 12, 2014 - Safeguard Scientifics
Safeguard Scientifics' John E. Shave III presented before the Stock & Bond Club of South Florida, updating the firms progress of the 19 partner portfolio companies. The shares have risen 40% since his former presentation in January ’13. www.safeguard.com

February 5, 2014 - ULURU, Inc.
Wednesday, February 5, 2014, The Stock and Bond Club of South Florida (“SBCSF”) was pleased to host ULURU, Inc., a specialty pharmaceutical company, focused on the development and marketing of innovative wound care products as our Presenter. ULURU’s products include ‘Altrazea’l, an “intelligent” powder dressing which adapts to and interacts with wounds, helps reduce or neutralize wound exudate [the cellular debris discharging from wounds] while also hydrating upon application. The company’s other major product is ‘Aphthsaol’, designed for ulcer treatment. ULURU’s products utilize its proprietary NanoFlex technology, and patent protection is extensive. SBCSF compliments ULURU’s CEO and President, Kerry Gray, for his excellent presentation, and it appreciates ULURU subsidizing our Members’ dinner cost. We are pleased to confirm Mr. Gray and ULURU as Lifetime Members of the SBCSF. President Kerry P. Gray President Kerry P. Gray President Kerry P. Gray dispays the company’s Altrazeal® powder dressing built on the Company’s Nanoflex technology. www.uluruinc.com

January 21, 2014 - Can Fite Biopharma, Lt.
The Stock & Bond Club and Irth Communications, Robert Haag present Can Fite Biopharma, Ltd.Can Fite Biopharma Ltd. presented at the Stock & Bond Club of South Florida on Tuesday, January 21st.  Pnina Fishman, Ph.D., CEO outlined the companies progress in the disease-fighting areas of Psoriasis, Rheumatiod Arthritis and Liver Cancer using compounds that target cancer and inflammatory cells. 2014 looks promising in that initial and interim phase trials will be analyzed, initiated or submitted to the US FDA. Based in Israel, Can Fite is a listed company here on the New York Stock Exchange (CANF). Dr. Fishman was bestowed an honorary member of the Stock & Bond Club by Carlo Corzine, who chaired the meeting. For further information, please visit the company’s website at www.canfite.com


Past Presenters

Past Presenters These are companies that have sponsored meetings:

  • AV Therapeutics (private)

  • Document Security Systems, Inc (DSS)

  • United Commodity AG

  • Careview Communications, Inc (CRVW)

  • Safeguard Scientifics (SFE)

  • MagNegas Corp (MNGE)

  • Staar Financial Advisors (Andre Weisbrod)

  • Asur Software (ASUR)

  • Meadow Bay Gold (MAYGF)

  • Paramount Gold (PZG)

  • Uranium Energy Corp (UEC)

  • Enerplus Corp (ERF)

  • CF Industries (CF)

  • Polymedix (PYMX)

  • Statoil ASA (STO)

  • BB&T Corp (BBT)

  • General Electric (GE)

  • Lexington Realty Trust (LXP)

2016/2015 presenters/Sponsored meetings


January 29, 2015 - Arch Therapeutics Inc. (OTCQB: ARTH) Arch Therapeutics Inc. Presented before The Stock & Bond Club. COMPANY OVERVIEW: Arch Therapeutics, Inc. is a medical device company developing a novel approach to stop  bleeding (hemostasis) and control leaking (sealant) during surgery and trauma care. Arch is  developing products based on an innovative self-assembling peptide technology platform to make surgery and interventional care faster and safer for patients. Arch's flagship  development stage product candidate, known as AC5 Surgical Hemostatic Device™, is being designed to achieve hemostasis in minimally invasive and open surgical procedures.www.archtherapeutics.com 

February 12, 2015 - The Grilled Cheese Truck Inc. (OTCQB: GRLD): Presented before The Stock & Bond Club. COMPANY OVERVIEW: The Grilled Cheese Truck, Inc. is an American entrepreneurial "emerging growth" company with a leading brand, serving gourmet grilled cheese melts, tots, soups and sides and other comfort foods menu that is widely followed throughout the nation by gourmet food experts and national media. The company currently operates and licenses grilled cheese food trucks in the Los Angeles, CA area and Phoenix, AZ, and is rolling out additional markets with the goal of becoming the largest operator in the gourmet grilled cheese space. The Company has entered
into master franchise agreements in the following territories; Texas, Illinois, South Dakota, North Dakota, San Diego, Iowa, Nebraska and Nevada, Louisiana, Idaho and Montana.www.thegrilledcheesetruck.com

March 4, 2015 - PURADYN Filter Technologies Inc. (OLTCQB: PFTI) presented at The Stock & Bond Club. Joseph V. Vittoria - Puradyn Board of Directors as Chairman on February 8, 2000 and to the office of Chief Executive Officer on October 24, 2006- gave a fantastic presentation! Company Overview: Our business values reflect Puradyn’s mission to remain the leader in the technology, development, and manufacturing of bypass oil filtration systems for combustion engines and hydraulic systems.  We are committed to continuously improving our oil filtration products in order to provide safe and significant cost-saving solutions to our customers.  We do this through the many benefits our technology provides:
Reduced oil purchases – up to 90% – through safely extended oil drain intervals
Reduced transport and disposal of waste oil
Reduced oil-related maintenance costs
Extension of equipment life through cleaner-running engines and/or equipment
Increased productivity – less equipment downtime
Improved fuel efficiency due to increased engine efficiency
Reduction of overall carbon footprint
Cooler-running engines and/or equipment

Puradyn Filter Technologies Incorporated designs, manufactures and markets the puraDYN® Bypass Oil Filtration System, which continuously filters lubricating oil by reducing solid contaminant to less than one micron, as well as removing liquid and gaseous contaminants, thereby maintaining the oil’s viscosity and safely and significantly extending oil drain intervals.  The puraDYN® System works with lubrication, hydraulic, and gear box oils below 50 weight for all internal combustion engines and equipment regardless of fuels used to power the engines. www.puradyn.com

March 24, 2015 -  Lightlake Therapeutics Inc. (OTCQB: LLTP): Kevin Pollack, Esq., Chief Financial Officer of Lightlake Therapeutics Inc., presented before The Stock & Bond Club with an exceptional & interesting product! COMPANY OVERVIEW: Lightlake Therapeutics Inc. is a biopharmaceutical company, is using its expertise in opioid antagonists to build a platform of innovative intranasal naloxone solutions to common addictions and related disorders. Lightlake is developing a treatment to reverse opioid overdoses, which have reached epidemic proportions in the United States. Lightlake has collaborated on clinical trials with the National Institute on Drug Abuse, part of the National Institutes of Health, and has entered into a licensing deal with a subsidiary of Adapt Pharma Limited. Lightlake also has completed a Phase II clinical trial to treat Binge Eating Disorder.  http://lightlaketherapeutics.com/

MAY 20, 2015 - PLASMATECH BIOPHARMACEUTICALS INC (NASDAQ: PTBI) presented at The South Florida Stock & Bond Club.
COMPANY OVERVIEW: PlasmaTech Biopharmaceuticals, Inc. is a biopharmaceutical company focused on advancing targeted treatments for significant unmet needs of critical patient care. Exploiting two distinct proprietary platforms, PlasmaTech Bio is active in the development and commercialization of cancer supportive care products and plasma-derived therapeutics. The company has a robust product pipeline that includes: a novel plasma fractionation process, a proven patented drug delivery platform, two commercial stage products and multiple follow-on products in development. http://www.plasmatechbio.com. About Your Presenter: Jeffrey Davis, PlasmaTech Biopahrmaceuticals Senior Consultant Formerly CEO of Access Pharmaceuticals, President, SCO Financial Group LLC; Vice President, Corporate Finance, at Deutsche Morgan Grenfell; Held Senior marketing and product management positions at AT&T Bell Laboratories; Marketing and Product Manager at
Philips Medical Systems North America.  MBA, The Wharton School, University of Pennsylvania; BS Biomedical Engineering, Boston University.

June 2, 2015 - Galmed Pharmaceutical Ltd. (NASDAQ: GLMD) presented at The South Florida Stock & Bond Club.
COMPANY OVERVIEW: Galmed is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel, once-daily, oral therapy for the treatment of liver diseases utilizing its proprietary first-in-class family of synthetic fatty-acid/bile-acid conjugates, or FABACs. Galmed believes that its product candidate, aramchol, has the potential to be a disease modifying treatment for fatty liver disorders, including NASH, which is a chronic disease that Galmed believes constitutes a large unmet medical need. 
About Your Presenter: Josh Blacher - Chief Financial Officer Mr. Blacher joined Galmed in 2014 with six years of experience in biotech-related business development, investing and operations, as well as 14 years in capital markets.http://galmedpharma.com  

July 7, 2015 -  Nephros Inc. (OTCQB: NEPH) presented at The South Florida Stock & Bond Club.
COMPANY OVERVIEW: Nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. Nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. Nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: •   Filtration – as low as 5 nanometers, •   Flow rate – minimal disruption, •   Filter life – up to 12 months. Nephros was founded in 1997, by healthcare professionals affiliated with Columbia University Medical Center, initially to address the needs of chronic renal failure patients. The company has developed an alternative to current hemodialysis therapy known as Mid-dilution hemodiafiltration (mid-HDF). Nephros’ proprietary blood purification technologies enable mid-HDF to be offered to chronic renal failure patients. Nephros mid-dilution filters remove a range of harmful substances, specifically substances known as middle molecules, which have been linked to conditions such as carpal tunnel syndrome, dialysis related amyloidosis, and degenerative bone disease in chronic renal failure patients. Nephros has extended its filtration technologies to meet the demand for liquid purification in other areas, in particular water purification. Nephros is currently developing its filter technology in individual water purifiers for military applications. Nephros has over 100 patents issued worldwide based on 15 different inventions which are primarily geared around our expertise as a filter development company, specializing in hollow fiber ultrafiltration membrane technology.  www.nephros.com 

​July 28, 2015 - Xplore Technologies Corp. (NASDAQ: XPLR) presented at The South Florida Stock & Bond Club.
COMPANY OVERVIEW: Xplore Technologies Corp., maker of the most rugged tablets on Earth, has been in the business of developing, integrating, and marketing industrial grade rugged tablets for our customers in the Energy, Utilities, Manufacturing and Distribution, Public Safety, Field Services, Transportation, and Military sectors for over 15 years. Xplore Tablets use the most powerful and modern processors and components and are tested more vigorously for shock, thermal, vibration, impact, ingress and emissions than any other PC in the industry.Xplore’s products enable the extension of traditional computing systems to a range of field and on-site personnel, regardless of location or environment. Xplore’s portfolio of products is sold on a global basis, with channel partners in the United States, Canada, Europe and Asia Pacific. Xplore’s main offices are located in Austin, Texas with regional sales offices throughout the U.S., Canada and Europe. Xplore is a public company that trades under the symbol XPLR on the NASDAQ Stock Exchange. ABOUT YOUR PRESENTER: Phil Sassower, serves as chief executive officer (CEO) and chairman of Xplore. Since 2006, Sassower has shaped the basic policy of Xplore in pursuit of sustainable growth and profitability. He spearheaded the company’s recent recapitalization, up-listing to NASDAQ and $10 million public offering through Aegis Capital, and has been active in building a wider and more solid interest in our story from the investment community. Sassower has more than 40 years of business and investment experience in successfully restructuring publicly-traded companies. By implementing new business strategies, he works with management teams and boards of directors to acquire, invest in, and build successful companies. Sassower is CEO of Phoenix Group, a New York based private equity firm, chairman and CEO of Communication Intelligence Corporation (OTCQB: CICI), a leading provider of electronic signature solutions, and is managing member of Phoenix Venture Fund, Xplore largest shareholder. He also served as chairman and CEO of Newpark Resources, an oil and gas services company focused on environmental remediation, and Bates Manufacturing Company, an owner of extensive coal deposits. Sassower graduated from Queens College in New York with a Bachelor of Science in accounting and cum laude from Harvard Law School's Juris Doctor program.  http://www.xploretech.com/

August 26, 2015 Accurexa  Inc. (OTCQB: ACXA) presented at The South Florida Stock & Bond Club. COMPANY OVERVIEW: Accurexa is a biotechnology company focused on developing and commercializing novel neurological therapies based on our proprietary BranchPoint device delivering therapeutics directly into specific regions of the brain.  Our BranchPoint device can deliver therapeutics through the radial deployment of a flexible delivery catheter to large and anatomically complex brain targets through a single initial brain penetration. Our BranchPoint device was developed at the University of California, San Francisco (UCSF) with $1.8 million in funding from the California Institute for Regenerative Medicine (CIRM).  It is based on a neurosurgical delivery platform, which we exclusively licensed from UCSF.  It can enable new approaches to neurological therapy and be modified for the delivery of a wide range of novel therapeutics, such as chemotherapeutics to brain tumors, stem cells to treat neurodegenerative diseases,  or gene therapy.  We are currently developing two programs in our pipeline: BranchPoint device which can deliver stem cells or gene therapy, for which we plan to file a 510(k) submission to the FDA in 2015. ACX-31 which could deliver temozolomide, a chemotherapy drug, directly to brain cancer sites with our BranchPoint device, and is contingent on BranchPoint's 510(k) approval.

ABOUT YOUR PRESENTER: George Yu - President and CEO: Mr. Yu has been the President and Chief Executive Officer of the Company since inception. He has over 15 years of experience in start-up companies, finance, operations and the medical field. His well-rounded background allowed him to start the Company as a founder and raise a common stock funding round. He has the experience to manage the prototype development, the clinical trials and to raise additional funding that is critical for the success of the Company. http://www.accurexa.com .

September 2, 2015  RestorGenex (OTCQB: RESX) presented at The South Florida Stock & Bond Club.
 RestorGenex  is a specialty biopharmaceutical company focused on eveloping a portfolio of first-in-class therapeutic products to treat diseases across the ophthalmologic, oncologic and dermatologic space. RestorGenex's lead product is a novel PI3K/Akt/mTOR pathway inhibitor which has completed two Phase I clinical trials for age-related macular degeneration and is in pre-clinical development for glioblastoma multiforme. The current pipeline also includes a "soft" anti-androgen compound for the treatment of acne vulgaris. RestorGenex's novel inhibition of the PI3K pathway and unique targeting of the androgen receptor show promise in a number of additional diseases, which the Company is evaluating for the purpose of creating safe and effective treatments and innovative therapies.  Financial Highlights: At December 31, 2014, RestorGenex had approximately $22 million in cash and anticipates a 2015 monthly burn rate of approximately $1,000,000.  ABOUT YOUR PRESENTER: Mark Weinberg, M.D. - Senior Vice President of Clinical Development. Dr. Weinberg is the Senior Vice President of Clinical Development at RestorGenex. Dr. Weinberg earned his M.D. from Duke University Medical School and remained there to complete a residency in internal medicine. He also holds an MBA from the Kellogg Business School of Northwestern University and a BA in economics from Yale University. Dr. Weinberg joined RestorGenex from Astellas Pharma Global Development where he was Vice President, Global Clinical Science and had also served as the Global Therapeutic Area Head, CNS and Pain. Prior to Astellas, he was Vice President, Medical Strategy and Medical Affairs at Lundbeck Inc. (formerly Ovation Pharmaceuticals). Previously, Dr. Weinberg held roles of increasing responsibility in clinical development at Takeda Global Research and Development and Abbott Laboratories. He has worked in several therapeutic areas during his career including oncology, CNS, pain, hematology, ophthalmology, rheumatology, and dermatology. http://www.restorgenex.com/

September 22, 2015, Nutroganics, Inc. presented at The South Florida Stock & Bond Club!
COMPANY OVERVIEW:Nutroganics, Inc. (OTC: NUTT), builds and acquires revenue-generating businesses
in the consumables portion of the healthy lifestyle marketplace.
. Growth through acquisition, e.g. Silverbow, NuStar
. Numerous additional opportunities (see pg. 13 on PPP)
. Growth via licenses, e.g. Clark’s Honey Farm and WholeSoy & Co.
. Current revenue at approximately $18mm run rate; up from $3mm run rate a year ago
. Cash flow positive since September 2014; net income positive since January 2015
. New contract wins, M&A opportunities provide significant upside potential
. Creates operating leverage through vertical integration
. Consolidation of operations
. Improved margins by reduction in transaction costs
. Increase in revenue through shared co-packing customer base, “own brand sales,” and relationship leveraging

ABOUT THE PRESENTER: Jay Wright, Chairman. Mr. Wright has over 20 years of experience in finance and public markets. As a director and C-level executive at 3 public companies over the past 15 years, he has structured numerous private and public transactions. He has expertise in all aspects of structuring private placements and in creating exits via M&A transactions and open market sales. Previously, Mr. Wright worked as an investment banker with Merrill Lynch in New York and as a M&A lawyer with Foley & Lardner in Chicago and Skadden, Arps in New York.  http://www.nutroganics.com/ 

​​October 20, 2015, Rocky Mountain High Brands (OTC Pink: RMHB),presented at The Boca Raton Country Club. 
COMPANY OVERVIEW: Rocky Mountain High Brands proudly introduces Rocky Mountain High - a range of wickedly delicious hemp-based beverages that are 100% legal and refreshing! http://rockymountainhighbrands.com/ PRESENTER: Jerry Grisaffi, Chairman.

November 4, 2015. Midwest Holdings Inc. (OTC Pink: MDWT), presented at The Boca Raton Country Club. COMPANY OVERVIEW: Midwest Holdings Inc. is a Lincoln, Nebraska based financial services and insurance holding company. Our insurance subsidiaries provide life insurance services. Midwest Holding Inc. was founded as a Nebraska holding company by Rick and Travis Meyer in October 2003. Through their efforts, more than $11 million was raised from 4,400 residents of Nebraska for the purpose of building and developing not only successful and profitable holding company, but also to charter a life insurance company to serve residents of the state. The $22 million is the largest successful intrastate offering in Nebraska's history. The Board of Directors of the Company represent all areas of the State and are committed to the motto of "by Nebraskans for Nebraskans." In September, 2009, Midwest capitalized American Life & Security Corp. the first life insurance company organized in the state in more than 30 years. Today, American Life is successfully writing life insurance on residents of Nebraska. Midwest continues to aggressively pursue its long-term growth strategy of building a large, profitable financial services company. Management has added several key individuals to help guide the company towards the attainment of these objectives. Towards attainment of these goals, Midwest intends to pursue mergers and acquisitions of other holding or life insurance companies. Additionally, management is looking for a Nebraska-based bank to join forces with to provide additional benefits for our shareholders and policyholders. ABOUT YOUR PRESENTER: Mark A. Oliver, FLMI - Chairman of the Board, Chief Executive Officer - has been with Midwest since 2009 and has served as CEO for the past 3 years. Oliver’s career spans more than 35 years in the life insurance industry. He spent 24 years with Citizens, Inc. (NYSE: CIA) in various capacities, the last 10 as President before leaving in 2007. He is the past President, Texas Chapter, Insurance Accounting & Systems Assoc. and former CEO of American Life & Security Corp.  www.midwestholding.com

December 1, 2015: Manhattan Scientifics Inc. (OTCQB: MHXT) Presented at the Boca Raton Country Club on Tuesday, December 1, 2015. Manhattan Scientifics is located in New Mexico, New York and Montreal. It is focused on technology transfer and commercialization of transformative technologies in the nano medicine space. The company is presently developing commercial medical prosthetics applications for its ultra-fine grain metals and plans to commercialize the cancer research work and nano medical applications. We are currently focused on two opportunities: a nanostructured metals technology, and a nanoparticle-based technology that provides highly sensitive cancer detection. The nanostructured metals technology has been revenue producing for several years. The cancer detection technology can detect cancer years earlier, and is still pre-revenue. http://www.mhtx.com .

January 28, 2016: ITUS Cortporation (NASDAQ: ITUS) presented at the Boca Raton Country Club.
COMPANY OVERVIEW: ITUS Corporation funds, develops, acquires and licenses emerging technologies in areas such as cancer diagnostics, encrypted communications, and semiconductor fabrication. Anixa Diagnostics, a subsidiary of ITUS, is developing a platform for inexpensive, non-invasive blood tests for the screening and early detection of solid tumors. The platform measures a unique set of biomarkers that have been associated with multiple stages and types of cancer. The company's strategy is based on the belief that early detection has the potential to significantly reduce cancer deaths and greatly improve the quality of life for patients. Anixa's long term goal is for its screening tests to become part of the normal battery of tests ordered for asymptomatic patients during routine doctor visits. ITUS's corporate headquarters is located in Los Angeles, California. ABOUT YOUR PRESENTER: Robert Berman, President and Chief Executive Officer, Director. 
​Mr. Berman has experience in a broad variety of areas including finance, acquisitions, marketing, and the development and licensing of emerging technologies. He was recently the CEO of IP Dispute Resolution Corporation, a consulting company focused on patent licensing. Prior to IPDR, Mr. Berman was the Chief Operating Officer and General Counsel of Acacia Research Corporation. Mr. Berman has been quoted in numerous articles on intellectual property and is a frequent speaker on technology licensing including programs at Harvard Law School and UCLA’s Anderson School of Business. Mr. Berman received a B.S. from the University of Pennsylvania’s Wharton School, and a J.D. from Northwestern Law School, where he is an adjunct faculty member. http://www.ituscorp.com/

February 23, 2016: Akers Biosciences (NASDAQ: AKER) presented at The South Florida Stock & Bond Club: (London AIM: AKR)
COMPANY OVERVIEW: Dedicated to accelerating diagnostic science to deliver real-time results. Akers Biosciences, Inc. (aka Akers Bio) was founded in 1989, with the objective of developing proprietary, in vitro diagnostic technologies that accelerate the rate at which clinicians, and in some cases consumers, can obtain health information. The tests and sample preparation devices that emerge from our rapid technology platforms are designed to provide the same level of accuracy as traditional laboratory testing methods, but at a fraction of the cost and turn-around time. Now known as Akers Bio, we are dedicated to the development of time- and cost-efficient, single-use devices that can be utilized almost anytime, anywhere. We believe that our products facilitate more convenient and frequent point-of-care testing, which may ultimately save or improve the overall quality of individuals’ lives. Our Products: Clinical Diagnostics: Our rapid diagnostic tests, specifically designed for medical clinicians:

o    Help facilitate or rule-out diagnoses and provide a pathway for real-time treatment decisions.
o    Provide affordable mass screening solutions for key infectious diseases, cardiac conditions and metabolic markers, without the use of expensive equipment or lengthy test procedures.  

Safety Diagnostics: Our safety products improve the ability of individuals, corporations, and law enforcement agencies to monitor the presence of substances within the human body that may adversely impact the ability to safely perform tasks such as driving or operating machinery. Our products facilitate testing on a more consistent or frequent basis because they are simple to perform, inexpensive and provide rapid results.  Wellness Products: The personal use products within our Akers Wellness™ line enable individuals to monitor their health and wellness with the help of easy-to-perform, non-invasive methods, such as simple breath tests.  Akers Bio is located in West Deptford, New Jersey, USA. Our stock is traded on both the NASDAQ Capital Market (AKER) and the London Stock Exchange’s AIM market (AKR). We are proud to employ a quality management system in accordance with the requirements of ISO 13485. ABOUT YOUR PRESENTER: Raymond F. Akers Jr., Ph.D.Co-founder and Executive Chairman. Raymond Akers founded the company in 1989. He has vast experience in the diagnostics industry having co-founded Drug Screening Systems, Inc., a publicly listed company, in 1987 and Akers Medical Technology Inc., in 1984. He was President and Chief Executive Officer of Akers Medical Technology Inc. until 1987 and later Chief Executive Officer and Vice President of Research and Development of Drug Screening Systems, Inc. until the sale of that company in 1989. He holds a Ph.D. in Neurochemistry from Northwestern University. Dr. Akers is the inventor of several of the company’s platform technologies including Particle ImmunoFiltration Assay (PIFA), the basis for the company’s flagship rapid test for heparin induced thrombocytopenia (HIT). http://www.akersbio.com/


February 29, 2016. Pluristem Therapeutics Inc.,  (NASDAQ: PSTI), presented at the Boca Raton Country Club. 
COMPANY OVERVIEW: Our vision at Pluristem Therapeutics is to leverage our position as a global leader in placenta-based cell science to develop and manufacture safe and effective cell therapy products. We believe our cutting edge technology can produce therapies that will help people affected by inflammation, ischemia, hematological disorders, and acute radiation syndrome, and establish us as a leading company in the cell therapy arena. We also believe that in cell therapy “the process is the product”, and precise control of the entire process, from obtaining cells from the source, to delivery to the patient, is vital to the success of a cell therapy. Our fully automated process, proprietary 3D cell expansion technology and increasing knowledge of the placental cell drive us to continue developing additional candidates for our product portfolio. Recently we have made significant progress in the execution of our strategy to shorten the time to commercialization of our PLX cells. The PLX cell program in critical limb ischemia has been selected for the European Medicines Agency’s Adaptive Pathways pilot project, which potentially allows for early marketing authorization of a therapy in a restricted patient population, and the possibility of later approval for use in broader patient populations. In Japan, we have applied to the Accelerated Pathway for Regenerative Medicine for  our PLX cells in critical limb ischemia. Japan’s Pharmaceuticals and Medical Devices Agency just validated the proposed quality and  large-scale manufacturing methods for PLX-PAD cells for use in clinical trials there. We are hopeful that these rapid pathways will allow us to shorten the time it will take to bring our advanced cell therapies to patients in need of innovative treatments. ABOUT YOUR PRESENTER: Yaky Yanay was appointed as Pluristem’s President and Chief Operating Officer in February 2014 and prior to that served as Pluristem’s Chief Financial Officer and Secretary since November 2006, and Executive Vice President since March 2013. Before joining Pluristem, Mr. Yanay was the Chief Financial Officer of Elbit Vision Systems Ltd., a public company. Prior to that Mr. Yanay served as manager of audit groups of the technology sector at Ernst & Young Israel. Mr. Yanay is Co-Chairman of Israel Advanced Technology Industries (IATI), the largest umbrella organization representing Israel’s high tech and life science industries. Yanay is representing Israel’s life sciences industry and has served on the Board of Directors of IATI for the past three years. Mr. Yanay also founded and served as Chairman ​of the “The Life Science Forum”. Mr. Yanay holds a bachelor’s degree with honors in business administration and accounting and is a Certified Public Accountant in Israel. www.pluristem.com 

Energy Fuels Inc., (NYSE: UUUU), presented at the Boca Raton Country Club on Monday, February 29, 2016! 
COMPANY OVERVIEW: Energy Fuels is a leading, US-based, integrated producer of uranium – the fuel for carbon-free,
emission-free nuclear energy. Our uranium production portfolio is unique in the World today.  Nuclear energy is expected to see strong growth in the coming years, as nations around the World work to provide plentiful and affordable energy, while combating global climate change and air pollution.  We utilize both conventional and in-situ recovery (“ISR”) technology and produce uranium from two strategic facilities – the White Mesa Mill in Utah (conventional) and the Nichols Ranch Plant in Wyoming (ISR). Our portfolio also boasts a book of premium-priced sales contracts with major nuclear utilities, an industry-leading U.S.-based NI 43-101 Mineral Resource portfolio among producers, and a pipeline of high-quality, large-scale development and exploration projects. As uranium prices increase, Energy Fuels has the resources and processing capacity to significantly increase uranium production in the U.S. ABOUT YOUR PRESENTER: Curtis H. Moore, ice President of Marketing and Corporate Development. Mr. Moore is the Vice President of Marketing and Corporate Development for Energy Fuels Inc.  He is in charge of product marketing for Energy Fuels, and is closely involved in mergers & acquisitions, investor relations, public relations, and corporate legal. He has been with Energy Fuels for over seven years, holding various roles of increasing responsibility. Prior to joining Energy Fuels, Mr. Moore worked in multi-family real estate development, government relations and public affairs, production homebuilding, and private law practice. Mr. Moore is a licensed attorney in the State of Colorado.  He holds Juris Doctor and Masters in Business Administration degrees from the University of Colorado at Boulder, and a bachelor of arts dual degree in Economics-Government from Claremont McKenna College in Claremont, California. www.energyfuels.com   

Can-Fite BioPharma Ltd.., (NYSE: CANF), presented at the Boca Raton Country Club on Monday, May 2, 2016! www.canfite.com​ 
COMPANY OVERVIEW: Can-Fite BioPharma Ltd. is an advanced clinical stage drug development company with a platform technology that addresses multi-billion markets in the treatment of inflammatory diseases, cancer, sexual dysfunction, and ophthalmic indications. The Company’s CF101 drug candidate is scheduled to enter Phase III trials in 2016 for two indications, rheumatoid arthritis and psoriasis. CF101 has been out-licensed in Korea and Canada, with $10 million received to date. Can-Fite’s liver cancer drug CF102 is in Phase II trials for patients with advanced liver cancer and is slated to enter Phase II for the treatment for non-alcoholic steatohepatitis (NASH). CF602, the Company’s third drug candidate, has shown efficacy in the treatment of erectile dysfunction in preclinical studies and is being prepared for an IND submission to the FDA and a Phase I trial. The Company’s drug candidates have an excellent safety profile with experience in over 1,000 patients in clinical studies to date. Can-Fite’s intellectual property portfolio consists of 120 patents issued and pending. ABOUT YOUR PRESENTER: Motti Farbstein - CFO. Motti Farbstein past managerial experience included seven years as VP of Mor Research Application (MRA), a company that was in charge of commercialization of intellectual property from all hospitals and research centers of Clalit Health Services, the largest healthcare provider in Israel, and was also the first clinical CRO in Israel. He has extensive experience in data management of clinical trials.

​​NeuroMetrix Inc., (NASDAQ: NURO)
presented at the Boca Raton Country Club Monday, May 23, 2016. COMPANY OVERVIEW: NeuroMetrix is an innovative health-care company that develops |wearable medical technology and point-of-care test that help patients and physicians better manage chronic pain, nerve diseases, and sleep disorders. The Company is located in Waltham, Massachusetts. It was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996 by Shai Gozani, M.D., Ph.D., NeuroMetrix President and Chief Executive Officer. The Company is publicly traded (Nasdaq: NURO). NeuroMetrix markets the following products: Quell™, SENSUS®, DPNCheck®, ADVANCE™ System. The Company’s expertise in biomedical engineering has been refined over nearly two decades of designing, building and marketing medical devices that stimulate nerves and analyze nerve response for diagnostic and therapeutic purposes. NeuroMetrix created the market for point-of-care nerve testing and were first to market with sophisticated, wearable technology for management of chronic pain. ABOUT YOUR PRESENTER: Shai N. Gozani, M.D., Ph.D., President, Chief Executive Officer&Director: Dr. Gozani founded NeuroMetrix, Inc. in 1996 as a spin-off from the Massachusetts Institute of Technology.   He currently serves as Chairman of the board of directors and as our President and Chief Executive Officer. Dr. Gozani has led the Company from a venture capital backed start-up, through an initial public offering on Nasdaq, through development of a successful diagnostics business, and presently into the wearable technology sector. Over 2.5 million patients have benefited from the Company’s technology over the past 15 years. Dr. Gozani has published over 30 peer-reviewed scientific articles and has been awarded 25 US and international patents. Dr. Gozani holds a B.A. degree in Computer Science, a M.S. degree in Electrical Engineering & Computer Science (Biomedical Engineering Focus) and a Ph.D. in Neurobiology, from the University of California, Berkeley. He also received an M.D. from Harvard Medical School and the Harvard-MIT Division of Health Sciences and Technology at M.I.T.  www.neurometrix.com  

Paringa Resources Limited: (OTCQB: PNGZF) (ASX: PNL) at the Boca Raton Country Club on Thursday, June 16, 2016. 
COMPANY OVERVIEW: Paringa Resources Limited is an emerging US based coal exploration and development Company focused on developing its high margin, low capex Buck Creek Mining Complex located in the growing Illinois Coal Basin. ABOUT YOUR PRESENTER: Mr. David Gay - Chief Executive Officer:  Mr. Gay is a Professional Mining Engineer with an MBA and has over 35 years of experience in developing coal projects in the USA. Mr Gay’s experience covers the entire coal development chain including leasing, permitting, exploration, construction, commissioning, production, mergers & acquisitions and financing activities (including project finance, high yield bonds, bank debt, structured finance and equity). Most recently he was Vice President, Mergers and Acquisitions and Business Development at Alpha Natural Resources, one of the USA’s largest coal producers. During his time, Alpha completed over US$10 billion worth of mergers and acquisitions and transitioned into one of the largest coal companies in the US and the third largest coking coal exporter globally. Prior to that, Mr Gay led several large regional coal companies and was Business Unit President at Pittston Coal Group (20 years’ experience) which at the time was the largest coking coal exporter worldwide. Mr Gay was appointed Chief Executive Officer – USA of the Company on 16 October 2013. 

ENDURANCE EXPLORATION GROUP: (EXPL) at the Boca Raton Country Club, Thursday, September 22, 2016. 
COMPANY OVERVIEW: Endurance Exploration Group LLC was formed in 2009 to explore, from an operational and financial perspective, the feasibility and potential economic return of recovering historic and modern day shipwreck cargos. We began by developing a research methodology with three goals. The first goal was to establish a comprehensive understanding of the larger economic, technological and social trends that lead to the transport of physical wealth across oceans during different historical periods, along with creating a "High Interest" list of shipwrecks and their cargos lost across various historical periods. Conflict, accidents and acts of nature claimed a percentage of all voyages, and many of the shipwrecked vessels are believed to have carried a valuable cargo. Our second objective was to identify, from this prior population of potential shipwreck losses, those shipwrecks that could be legally salvaged and recovered, and the cargos sold, with a positive return on the capital investment required for their location and recovery. Our third goal was to move those projects which had the potential to generate positive investment returns into an operational phase with a high, risk-adjusted, chance of success; and, to develop a portfolio of projects in various stages of research, search, survey and recovery. ABOUT YOUR PRESENTER: Mr. Carl Dilley – Chief Operating Officer, Director Mr. Dilley has served as president of Island Stock Transfer, a division of Island Capital Management, LLC, from 2003 to present and acts as senior executive officer responsible for oversight of day to day operations. Carl Dilley is a Director and COO of Endurance Exploration Group, Inc. www.enduranceexplorationgroup.com


DarioHealth Corp. (Dario): Presented on Wednesday, October 26th 2016. COMPANY OVERVIEW: DarioHealth Corp. (NASDAQ: DRIO) creates innovative mobile and digital tools that empower and engage users to lead healthier lives. DarioHealth’s “Real time. Real data. Real people” approach and strategy is positioning the company as a major player in the mHealth industry; an industry currently worth $10B and expected to reach $31B by 2020*. DarioHealth’s flagship product, the Dario™ Smart Diabetes Management Solution, is a platform for diabetes management that combines an all-in-one blood glucose meter, native smart phone app (iOS & Android), website portal and a wide variety of treatment tools to support more proactive and better informed decisions by users living with diabetes, their doctors and healthcare systems. The Dario Smart Diabetes Management Solution was granted U.S. FDA marketing clearance in December 2015 and is set to launch in the current quarter in the U.S. – the largest market in the world for glucose monitoring. LabStyle has been granted patents, and is pursuing additional applications - in multiple areas covering the specific processes related to blood glucose level measurement, as well as more general methods for rapid body fluids testing using mobile devices and cloud-based services. Dario™ is currently available in the UK, New Zealand, Netherlands, Australia, Israel, Canada, Belgium and Italy. Dario received reimbursement coverage in the UK, Australia, Israel, Italy and Canada. Sequential quarterly revenues are growing rapidly, reflecting strong market adoption.

ABOUT YOUR PRESENTERS: Erez Raphael - CEO/Chairman. Erez Raphael has over 20 years of systems and software development experience in various industries including mobile, life science, medical device, health IT, mHealth and digital health solutions. Mr. Zvi Ben-David - CFO: 25 years of financial and accounting experience, particularly with public and private medical device public companies. 

Mobi724 Global Solutions (CES: MOS): Presented on Wednesday, December 7, 2016 at the Boca Raton Country Club.
COMPANY OVERVIEW: Mobi724 Global Solutions, Inc., listed on the Canadian Stock Exchange (CSE: MOS), is a Montreal, Canadian based company engaged in digital incentives, such as card-linked offers and digital marketing; payment solutions, including mobile payment; loyalty programs, and data analytics. The Company’s operates through two segments: Payment solution and E-couponing. Its solutions enable retailers, manufacturers, offer providers, mobile operators and card issuers to create, manage, deliver, and track and measure incentive campaigns to various mobile devices and allow its redemption at various points of sales. Its credit and debit payment solutions, focusing on authentication, approved security and quick merchant adoption, allow users to process payments with a range of devices. Its payment card industry (PCI) and Europay, MasterCard and Visa (EMV) cloud-based switch is a payment and digital incentives solution. It focuses on digital couponing solutions and payment solutions markets. The website is www.Mobi724.com .

OWC Pharmaceuticals Research Corp. (OTCQB: OWCP): Presented at the Boca Raton Country Club on Wednesday, February 1, 2017. COMPANY OVERVIEW: OWC Pharmaceutical Research Corp. [OTCQB: OWCP] is engaged in the business, through its wholly-owned Israeli subsidiary, One World Cannabis Ltd., of conducting medical research and clinical trials, in full compliance with all international regulatory protocols, for the development of cannabis-based products and treatments specifically designed for Multiple Myeloma, Psoriasis, Fibromyalgia, PTSD, Migraines, and unique delivery systems. These include a Cannabis Sublingual Tablet and a Cannabis Based Psoriasis Topical Cream. ABOUT YOUR PRESENTER: Ziv Turner, VP Sales and Business Development OWC Pharmaceutical Research Corp and Managing Director of One World Cannabis Ltd. Mr. Turner is a proven entrepreneur with extensive business development expertise, as well as significant experience within the international business community. A successful engineer, Mr. Turner has 20 years’ experience working in senior management positions for leading telecom companies. Beginning 1995, he was head of sales for various leaders in the telecommunication industry. His responsibilities included establishing turnkey operating profit centers with regional partners, negotiating with local governments in the APAC countries, establishing OEM, and other partnerships with global integrators and distributors, and implementing regional sales and training programs. Mr. Turner is also the founder of Vocavu, an internet content company.